Google
LNTH 株価分析 — Lantheus Holdings Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
LNTH に関するよくある質問
LNTHのPER（株価収益率）は？
Lantheus Holdings Inc（LNTH）は現在PER 23.25倍で取引されています。
LNTHのROE（自己資本利益率）は？
Lantheus Holdings IncのROEは23.02%です。
LNTHの配当利回りは？
Lantheus Holdings Incの配当利回りは0.00%です。
LNTHの品質スコア（Quality Score）は？
当社のAIはLNTHの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
LNTHは今が買い時ですか？
当社AIのタイミングスコアは100点中70点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
LNTHはどのセクターに属しますか？
Lantheus Holdings IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
LNTH AI Analysis Summary
Our AI summary for LNTH: Lantheus Holdings Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 23.25, ROE of 23.02%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 101.19
Price
1.55
(1.56%)
Day Change
|
|
|---|
LNTH, ファンダメンタルスコアはgood ( ファンダメンタル = 77) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
1003
|
| Magic Formula Rank by ROE |
1003
|
| Magic Formula Rank by ROIC |
1049
|
| Price | 101.19 |
| PBV / Sector |
5.35 / 9.54
|
| Earning Per Share | 4.35 |
| PE / Sector |
23.25 / 28.71
|
| PEG or PE/Growth / Sector |
0.07 / -0.10
GREAT
|
| Average 1M Daily Value |
131.20 M
GREAT
|
| Average 1W Daily Value |
282.17 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
56% |
| ポイントになる統計 |
|
70% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:48 |
| Symbol | LNTH |
| Name | LANTHEUS HOLDINGS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 65.11 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,487.17 / 10,605.93 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Burlington Road, Bedford, MA, United States, 01730
Phone: 978 671 8001
Website: https://www.lantheus.com
Employees: 1,193
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
